The treatment landscape for Lupus nephritis treatment is evolving as targeted biologic therapies gain greater importance in managing autoimmune kidney complications. Among the notable therapies, BENLYSTA (belimumab) and GAZYVA (obinutuzumab) have emerged with distinct mechanisms, clinical evidence, and administration requirements. Their expanding roles are attracting attention from physicians,...